1. Trial profile
John A Dormandy et al. Lancet 2005;366:

2. Baseline characteristics
John A Dormandy et al. Lancet 2005;366:

3. Macrovascular morbidity at study entry and associated medications
John A Dormandy et al. Lancet 2005;366:

4. Kaplan-Meier curve of time to primary endpoint
John A Dormandy et al. Lancet 2005;366:

5. Kaplan-Meier curve of time to main secondary endpoint
John A Dormandy et al. Lancet 2005;366:

6. Numbers of first events contributing to the primary composite and main secondary endpoints
John A Dormandy et al. Lancet 2005;366:

7. Effect of pioglitazone and placebo on each component of the primary endpoint
John A Dormandy et al. Lancet 2005;366:

8. Hazard associated with relevant baseline characteristics for the main secondary endpoint
John A Dormandy et al. Lancet 2005;366:

9. Change in proportion of patients using concomitant medications
John A Dormandy et al. Lancet 2005;366:

10. Kaplan-Meier curve of time to permanent insulin use
John A Dormandy et al. Lancet 2005;366:

11. Change in laboratory data from baseline to final visit
John A Dormandy et al. Lancet 2005;366:

12. Serious adverse event summary
John A Dormandy et al. Lancet 2005;366:

13. Reports of heart failure
John A Dormandy et al. Lancet 2005;366: